bgb-23339

BGB-23339 is a potent, highly selective, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor discovered and developed by BeiGene. It targets the regulatory pseudokinase (JH2) domain of TYK2, which is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders such as psoriasis and inflammatory bowel disease. In preclinical studies, BGB-23339 demonstrated strong selectivity and potent inhibition of interleukin (IL)-12, IL-23, and Type 1 interferons (IFNs), key pro-inflammatory cytokines involved in inflammation[1][3][5]. The drug is currently being evaluated in Phase 1 clinical trials for safety, tolerability, pharmacokinetics, and preliminary activity.